Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.53 CAD | -3.16% | +4.08% | -54.33% |
14/05 | Transcript : Aptose Biosciences Inc., Q1 2024 Earnings Call, May 14, 2024 | |
14/05 | Aptose Biosciences Q1 Net Loss Falls, on Lower Expenses | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-54.33% | 1.83Cr | |
+52.36% | 5.81TCr | |
-3.86% | 4.05TCr | |
+36.70% | 3.9TCr | |
-12.01% | 2.66TCr | |
+14.13% | 2.67TCr | |
-21.62% | 1.9TCr | |
+0.21% | 1.22TCr | |
+25.96% | 1.19TCr | |
+23.02% | 1.2TCr |
- Stock Market
- Equities
- APS Stock
- News Aptose Biosciences Inc.
- Aptose Biosciences Brief: Also Notes TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed AML is Supported by Extensive TUS and TUS+VEN Data from Completed Trials with R/R AML